Changes to This Summary (04/04/2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that data reported to the U.S. Food and Drug Administration raises concern about QT prolongation and potentially fatal arrhythmias with a single intravenous (IV) dose of 32 mg, and that current drug labeling calls for a maximal single IV dose of 16 mg (cited U.S. Food and Drug Administration as reference 27).
This summary is written and maintained by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.